SubHero Banner

Wegovy® (semaglutide) – Updated dosing

July 21, 2023 - The FDA approved an update to the drug label for Wegovy (semaglutide) to include 1.7 mg subcutaneous weekly as an additional maintenance dose for use as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

Download PDF